New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
14:33 EDTISISIsis Pharmaceuticals provides update on CHMP Opinion on KYNAMRO
Isis Pharmaceuticals announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application for KYNAMROTM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia. The FDA approved KYNAMRO in the United States in January for the treatment of patients with Homozygous Familial Hypercholesterolaemia.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
14:30 EDTISISIsis Pharmaceuticals to hold an investor event
Management hosts an investor event to discuss the ISIS-SMN Rx data presented at the 2014 American Academy of Neurology's Annual Meeting in Philadelphia on April 29 at 6 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use